Tolerogenic Synthetic Nanocarriers to Reduce Immune Responses to Therapeutic Proteins
Summary
The EPO published patent EP3679933A1 granting Cartesian Therapeutics exclusive rights to tolerogenic synthetic nanocarriers designed to reduce immune responses against therapeutic proteins. The patent covers compositions and methods for administering tolerogenic nanocarriers to patients receiving protein-based therapeutics, potentially applicable across EU member states including DE, FR, GB, NL, and IT.
What changed
The EPO published patent application EP3679933A1 granting Cartesian Therapeutics exclusive rights to tolerogenic synthetic nanocarriers and their use in reducing anti-drug immune responses. The patent covers nanocarrier compositions, methods of manufacturing, and therapeutic applications for patients receiving protein-based biologics.
Pharmaceutical and biotech companies developing therapeutic proteins or biosimilars should monitor this patent when planning clinical programs or market entry strategies in Europe. Freedom-to-operate analyses for novel biologic formulations should account for this intellectual property covering tolerogenic delivery systems.
What to do next
- Monitor patent landscape for Freedom to Operate issues in therapeutic protein development
- Review EPO register EP3679933 for claim scope and designated state coverage
Archived snapshot
Apr 8, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
TOLEROGENIC SYNTHETIC NANOCARRIERS TO REDUCE IMMUNE RESPONSES TO THERAPEUTIC PROTEINS
Publication EP3679933A1 Kind: A1 Apr 01, 2026
Applicants
Cartesian Therapeutics, Inc.
Inventors
FRASER, Christopher, KISHIMOTO, Takashi, Kei, MALDONADO, Roberto A.
IPC Classifications
A61K 31/445 20060101AFI20200525BHEP A61K 39/38 20060101ALI20200525BHEP A61K 39/395 20060101ALI20200525BHEP A61K 9/16 20060101ALI20200525BHEP A61K 9/14 20060101ALI20200525BHEP A61K 47/30 20060101ALI20200525BHEP A61P 29/00 20060101ALI20200525BHEP A61K 31/00 20060101ALI20200525BHEP A61K 39/36 20060101ALI20200525BHEP B82Y 5/00 20110101ALI20200525BHEP A61K 39/00 20060101ALI20200525BHEP
Designated States
AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR
Related changes
Get daily alerts for ChangeBridge: EPO Bulletin - Pharma (A61K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from EPO.
The plain-English summary, classification, and "what to do next" steps are AI-generated from the original text. Cite the source document, not the AI analysis.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when ChangeBridge: EPO Bulletin - Pharma (A61K) publishes new changes.